You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Vilazodone hydrochloride
Vilazodone hydrochloride is a potent 5-HT1A partial agonist and serotonin-selective reuptake inhibitor (SSRI) (IC50 values are 0.2 and 0.5 nM respectively). Antidepressant.
Compound Libraries for Vilazodone hydrochloride
Technical Data for Vilazodone hydrochloride
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Vilazodone hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Vilazodone hydrochloride
The following data is based on the product molecular weight 477.99. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||10.46 mL||52.3 mL||104.6 mL|
|1 mM||2.09 mL||10.46 mL||20.92 mL|
|2 mM||1.05 mL||5.23 mL||10.46 mL|
|10 mM||0.21 mL||1.05 mL||2.09 mL|
Product Datasheets for Vilazodone hydrochloride
References for Vilazodone hydrochloride
References are publications that support the biological activity of the product.
Hughes et al (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur.J.Pharmacol. 510 49 PMID: 15740724
If you know of a relevant reference for Vilazodone hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Vilazodone hydrochloride, Vilazodone hydrochloride supplier, SB659746A, EMD68843, Potent, 5-HT1A, partial, agonists, agonism, serotonin-selective, reuptake, inhibitors, inhibits, SSRI, antidepressant, EMD, 68843, SB, 659746A, Receptors, 5-HT, Transporters, 6202, Tocris Bioscience
1 Citation for Vilazodone hydrochloride
Citations are publications that use Tocris products. Selected citations for Vilazodone hydrochloride include:
Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. Biochem Pharmacol 175 PMID: 32088264
Do you know of a great paper that uses Vilazodone hydrochloride from Tocris? Please let us know.
Reviews for Vilazodone hydrochloride
There are currently no reviews for this product. Be the first to review Vilazodone hydrochloride and earn rewards!
Have you used Vilazodone hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.